Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and mechanistic laboratory study
PubMed 33320834 · doi:10.1172/jci.insight.140848
What was done
The authors investigated whether vasopressin mediates fructose-induced metabolic syndrome. Mice were administered oral fructose, glucose, or high-fructose corn syrup to assess copeptin (vasopressin surrogate) responses and fructokinase involvement. The effects of suppressing vasopressin via increased hydration were tested, and knockout mouse models (V1bR-KO and V1a-KO) were evaluated alongside measurements of hepatic V1bR and fructokinase expression.
What was found
The abstract reports no numerical values. Qualitatively, oral sugar intake elevated copeptin levels in a fructokinase-dependent manner. Vasopressin suppression via hydration both prevented and ameliorated metabolic syndrome. V1bR-KO mice were completely protected from fructose-induced metabolic syndrome, whereas V1a-KO mice exhibited worsened metabolic syndrome. Fructose ingestion induced de novo hepatic V1bR expression, which in turn amplified fructokinase expression.
Why it matters
This work outlines a mechanistic link between water conservation pathways and fat accumulation, identifying the vasopressin V1b receptor as a mediator of fructose-induced metabolic dysfunction. It offers a mechanistic rationale for testing increased water intake in human metabolic disease.
Limits
All findings are derived from preclinical mouse models with no human clinical data. The abstract provides no specific sample sizes, sugar dosages, treatment durations, or quantitative effect sizes.
Cited by
- supports Vasopressin acts through the V1b receptor to mediate obesity and the metabolic effects of sugar, and blocking the V1b receptor blocks these effects in animals.
- supports Dietary consumption of either sugar or salt increases circulating levels of vasopressin in animals.